Biogen Inc Q1 2021 Earnings Call Summary - Thomson StreetEvents

Biogen Inc Q1 2021 Earnings Call Summary

Biogen Inc Q1 2021 Earnings Call Summary - Thomson StreetEvents
Biogen Inc Q1 2021 Earnings Call Summary
Published Apr 22, 2021
19 pages (10188 words) — Published Apr 22, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of BIIB.OQ earnings conference call or presentation 22-Apr-21 12:00pm GMT

  
Brief Excerpt:

...A. Overview: Knows 2021 will be a financial reset year for Co., but pleased with operational performance during Q1. 1. 2. Total revenues $2.7b and non-GAAP EPS $5.34. 3. Results driven by solid performance across MS, SMA and biosimilars, together with continued strong cost management. B. Aducanumab Launch: Ready to launch aducanumab in US should Co. receive regulatory approval. 1. 2. Anticipates an FDA decision by the June 7 PDUFA date....

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Biogen Inc
Ticker
BIIB.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : And congrats on the quarter. On the EMBARK trial, I believe you reduced the planned enrollment from 2,400 to 1,800. I was just wondering, could you give us some color on the drivers of this. Was it just slower enrollment than your expectation? But most importantly, I wondered if you could give us -- do you have any data around the enrollment rates from the active aducanumab arms versus placebo arms for the feeder trial?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Given you're so deep in the FDA's review of aducanumab, other than perhaps stage of Alzheimer's disease of patients, what are your latest thoughts or expectations on any specific limitations in labeling of adu, perhaps by APOE4 carrier status? Are there more genetic-oriented variables?

Table Of Contents

Biogen Inc Q2 2021 Earnings Call Summary – 2021-07-22 – US$ 54.00 – Edited Brief of BIIB.OQ earnings conference call or presentation 22-Jul-21 12:00pm GMT

Biogen Inc at SVB Leerink CNS Forum (Virtual) Transcript – 2021-06-29 – US$ 54.00 – Edited Transcript of BIIB.OQ presentation 29-Jun-21 5:50pm GMT

Biogen Inc to Discuss the Approval of ADUHELM Call Transcript – 2021-06-08 – US$ 54.00 – Edited Transcript of BIIB.OQ conference call or presentation 8-Jun-21 12:00pm GMT

Biogen Inc Annual Shareholders Meeting Transcript – 2021-06-02 – US$ 54.00 – Edited Transcript of BIIB.OQ shareholder or annual meeting 2-Jun-21 1:00pm GMT

Biogen Inc Q1 2021 Earnings Call Transcript – 2021-04-22 – US$ 54.00 – Edited Transcript of BIIB.OQ earnings conference call or presentation 22-Apr-21 12:00pm GMT

Biogen Inc at the Stifel 3rd Annual CNS Day Transcript – 2021-03-31 – US$ 54.00 – Edited Transcript of BIIB.OQ presentation 31-Mar-21 4:00pm GMT

Biogen Inc Evaluation Of Aducanumab Efficacy And Safety In Early Alzheimer's Disease Discussion at AD/PD Conference Call Transcript – 2021-03-13 – US$ 54.00 – Edited Transcript of BIIB.OQ conference call or presentation 13-Mar-21 11:45am GMT

Biogen Inc Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD Transcript – 2021-03-13 – US$ 54.00 – Edited Transcript of BIIB.OQ corporate analyst meeting</ 13-Mar-21 12:00pm GMT

Biogen Inc Pre-Recorded Presentation of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Transcript – 2021-03-10 – US$ 54.00 – Edited Transcript of BIIB.OQ corporate analyst meeting</ 10-Mar-21 11:45am GMT

Biogen Inc Live Discussion of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Transcript – 2021-03-10 – US$ 54.00 – Edited Transcript of BIIB.OQ corporate analyst meeting</ 10-Mar-21 4:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Biogen Inc Q1 2021 Earnings Call Summary" Apr 22, 2021. Alacra Store. May 23, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2021-Biogen-Inc-Earnings-Call-B14658364>
  
APA:
Thomson StreetEvents. (2021). Biogen Inc Q1 2021 Earnings Call Summary Apr 22, 2021. New York, NY: Alacra Store. Retrieved May 23, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2021-Biogen-Inc-Earnings-Call-B14658364>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.